{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T09:22:38Z","timestamp":1782984158732,"version":"3.54.5"},"reference-count":44,"publisher":"American Medical Association (AMA)","issue":"10","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Netw Open"],"abstract":"Importance<\/jats:title>The expansion in the number of disease-modifying therapies (DMTs) for immune-mediated neurologic diseases raises critical questions about trends in their use and cost over time and whether this growth could be contributing to escalating financial burdens within the Medicare system.<\/jats:p><\/jats:sec>Objective<\/jats:title>To examine trends in claims and Medicare Part D payments for DMTs for immune-mediated neurologic diseases.<\/jats:p><\/jats:sec>Design and Setting<\/jats:title>This retrospective economic evaluation analyzed Medicare Part D Prescriber Public Use Files from January 1, 2013, to December 31, 2022, restricting to prescription drug claims categorized under the clinician-defined neurology taxonomy. Only prescription drugs used as DMTs for multiple sclerosis, neuromyelitis optica spectrum disorder, and other immune-mediated neurologic disorders were included. To ensure accuracy, these medications were validated by 2 pharmacists. The data were analyzed between October 1, 2023, and November 12, 2024.<\/jats:p><\/jats:sec>Main Outcomes and Measures<\/jats:title>Ten-year trends in total payments, number of claims, and payment per claim for DMTs were assessed for their contribution to overall cost increases. Inflation adjustments were applied using both medical care\u2013specific and prescription drug\u2013specific indices.<\/jats:p><\/jats:sec>Results<\/jats:title>Between 2013 and 2022, 63 unique drugs used as DMTs for multiple sclerosis, neuromyelitis optica spectrum disorder, and other immune-mediated neurologic disorders (eg, autoimmune encephalitis, myasthenia gravis) accounted for 6\u202f526\u202f278 claims and contributed $35 billion in Medicare drug expenditures. Between 2013 and 2022, annual claims for DMTs increased by 3.8% (from 549\u202f766 to 570\u202f298 claims). However, total payments for DMTs saw a disproportionate increase of 70.3% (95% CI, 13.5%-130.3%) from 2013 to 2022. After adjusting for medical care or prescription drug inflation, 2022 payments per claim increased by 29.1% (95% CI, 15.6% to 51.6%) and 35.9% (95% CI, 29.5%-50.3%), respectively, indicating that the rise in drug costs exceeded adjustments for medical care or prescription drug inflation rates. For the 29 DMTs available over the entire 10-year period, total claims decreased by 14.8% (from 546 026 to 465 089). Despite this reduction in claims, total payments increased by 60.5% (95% CI, 50.9%-90.6%). After adjusting for medical care inflation, the total payment increased significantly by 26.2% (95% CI, 10.5%-49.4%).<\/jats:p><\/jats:sec>Conclusions and Relevance<\/jats:title>Over the past decade, Medicare Part D expenditures for DMTs targeting immune-mediated neurologic diseases have increased substantially, despite relatively stable claim volumes. These findings show that increases have consistently outpaced inflation rates, adding substantial economic pressure to federally funded neurologic care.<\/jats:p><\/jats:sec>","DOI":"10.1001\/jamanetworkopen.2025.38277","type":"journal-article","created":{"date-parts":[[2025,10,20]],"date-time":"2025-10-20T15:31:01Z","timestamp":1760974261000},"page":"e2538277","source":"Crossref","is-referenced-by-count":1,"title":["Medicare Part D Use and Costs for Immune-Mediated Neurologic Therapies"],"prefix":"10.1001","volume":"8","author":[{"given":"Ka-Ho","family":"Wong","sequence":"first","affiliation":[{"name":"Department of Neurology, University of Utah School of Medicine, Salt Lake City"},{"name":"Department of Population Health Science, University of Utah School of Medicine, Salt Lake City"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Esther","family":"Zeng","sequence":"additional","affiliation":[{"name":"Department of Undergraduate Studies, University of California, Berkeley"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tammy L.","family":"Smith","sequence":"additional","affiliation":[{"name":"Department of Neurology, University of Utah School of Medicine, Salt Lake City"},{"name":"Veterans Affairs Health System, Salt Lake City Health Care, Salt Lake City, Utah"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jordan B.","family":"King","sequence":"additional","affiliation":[{"name":"Department of Population Health Science, University of Utah School of Medicine, Salt Lake City"},{"name":"Institute of Health Research, Kaiser Permanente Colorado, Aurora"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erica","family":"Marini","sequence":"additional","affiliation":[{"name":"University of Utah School of Pharmacy, Salt Lake City"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abigail","family":"Sorenson","sequence":"additional","affiliation":[{"name":"Department of Undergraduate Studies, University of California, Berkeley"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heewon","family":"Hwang","sequence":"additional","affiliation":[{"name":"Department of Neurology, University of Utah School of Medicine, Salt Lake City"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chloe","family":"Stein","sequence":"additional","affiliation":[{"name":"Department of Neurology, University of Utah School of Medicine, Salt Lake City"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Trieste","family":"Francis","sequence":"additional","affiliation":[{"name":"Department of Neurology, University of Utah School of Medicine, Salt Lake City"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John W.","family":"Rose","sequence":"additional","affiliation":[{"name":"Department of Neurology, University of Utah School of Medicine, Salt Lake City"},{"name":"Veterans Affairs Health System, Salt Lake City Health Care, Salt Lake City, Utah"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vivek K.","family":"Reddy","sequence":"additional","affiliation":[{"name":"Department of Neurology, University of Utah School of Medicine, Salt Lake City"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adam Helme","family":"de Havenon","sequence":"additional","affiliation":[{"name":"Department of Neurology, Yale University, New Haven, Connecticut"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stacey L.","family":"Clardy","sequence":"additional","affiliation":[{"name":"Department of Neurology, University of Utah School of Medicine, Salt Lake City"},{"name":"Veterans Affairs Health System, Salt Lake City Health Care, Salt Lake City, Utah"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","published-online":{"date-parts":[[2025,10,20]]},"reference":[{"issue":"16","key":"zoi251061r1","doi-asserted-by":"publisher","first-page":"e2132","DOI":"10.1212\/WNL.0000000000011712","article-title":"Five-Year trends in payments for neurologist-prescribed drugs in Medicare Part D.","volume":"96","author":"de Havenon","year":"2021","journal-title":"Neurology"},{"issue":"7","key":"zoi251061r2","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1007\/s11910-021-01118-x","article-title":"Economics of multiple sclerosis disease-modifying therapies in the USA.","volume":"21","author":"Hartung","year":"2021","journal-title":"Curr Neurol Neurosci Rep"},{"key":"zoi251061r3","doi-asserted-by":"publisher","DOI":"10.1177\/1756286420987031","article-title":"Health economics of disease-modifying therapy for multiple sclerosis in the United States.","volume":"14","author":"Hartung","year":"2021","journal-title":"Ther Adv Neurol Disord"},{"issue":"21","key":"zoi251061r4","doi-asserted-by":"publisher","first-page":"2185","DOI":"10.1212\/WNL.0000000000001608","article-title":"The cost of multiple sclerosis drugs in the US and the pharmaceutical industry: too big to fail?","volume":"84","author":"Hartung","year":"2015","journal-title":"Neurology"},{"issue":"2","key":"zoi251061r5","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1377\/hlthaff.2018.05357","article-title":"Trends in coverage for disease-modifying therapies for multiple sclerosis in Medicare Part D.","volume":"38","author":"Hartung","year":"2019","journal-title":"Health Aff (Millwood)"},{"issue":"18","key":"zoi251061r6","doi-asserted-by":"publisher","first-page":"e1810","DOI":"10.1212\/WNL.0000000000200150","article-title":"The economic burden of multiple sclerosis in the United States: estimate of direct and indirect costs.","volume":"98","author":"Bebo","year":"2022","journal-title":"Neurology"},{"issue":"10206","key":"zoi251061r7","doi-asserted-by":"publisher","first-page":"1352","DOI":"10.1016\/S0140-6736(19)31817-3","article-title":"Inebilizumab for the treatment of neuromyelitis optica spectrum disorder (N-MOmentum): a double-blind, randomised placebo-controlled phase 2\/3 trial.","volume":"394","author":"Cree","year":"2019","journal-title":"Lancet"},{"issue":"7","key":"zoi251061r8","doi-asserted-by":"publisher","first-page":"614","DOI":"10.1056\/NEJMoa1900866","article-title":"Eculizumab in aquaporin-4-positive neuromyelitis optica spectrum disorder.","volume":"381","author":"Pittock","year":"2019","journal-title":"N Engl J Med"},{"issue":"22","key":"zoi251061r9","doi-asserted-by":"publisher","first-page":"2114","DOI":"10.1056\/NEJMoa1901747","article-title":"Trial of satralizumab in neuromyelitis optica spectrum disorder.","volume":"381","author":"Yamamura","year":"2019","journal-title":"N Engl J Med"},{"issue":"1","key":"zoi251061r12","doi-asserted-by":"publisher","DOI":"10.1136\/bmjmed-2022-000241","article-title":"New and emerging treatments for myasthenia gravis.","volume":"2","author":"DeHart-McCoyle","year":"2023","journal-title":"BMJ Med"},{"issue":"8","key":"zoi251061r13","doi-asserted-by":"publisher","first-page":"897","DOI":"10.1136\/jnnp-2020-325302","article-title":"Autoimmune encephalitis: proposed recommendations for symptomatic and long-term management.","volume":"92","author":"Abboud","year":"2021","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"2","key":"zoi251061r14","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1016\/S1474-4422(12)70310-1","article-title":"Treatment and prognostic factors for long-term outcome in patients with anti-NMDA receptor encephalitis: an observational cohort study.","volume":"12","author":"Titulaer","year":"2013","journal-title":"Lancet Neurol"},{"issue":"3","key":"zoi251061r15","doi-asserted-by":"publisher","DOI":"10.1212\/NXI.0000000000200109","article-title":"Therapies in stiff-person syndrome: advances and future prospects based on disease pathophysiology.","volume":"10","author":"Dalakas","year":"2023","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"issue":"1","key":"zoi251061r17","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1016\/j.jval.2010.10.013","article-title":"Exact method for computing absolute percent change in a dichotomous outcome from meta-analytic effect size: improving impact and cost-outcome estimates.","volume":"14","author":"Miller","year":"2011","journal-title":"Value Health"},{"issue":"10","key":"zoi251061r20","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000210029","article-title":"Costs are still on the rise for commonly prescribed branded neurologic medications.","volume":"103","author":"Gusovsky","year":"2024","journal-title":"Neurology"},{"issue":"7","key":"zoi251061r21","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1007\/s11940-021-00677-1","article-title":"Early aggressive treatment approaches for multiple sclerosis.","volume":"23","author":"Simpson","year":"2021","journal-title":"Curr Treat Options Neurol"},{"issue":"11","key":"zoi251061r22","doi-asserted-by":"publisher","first-page":"1333","DOI":"10.1001\/jamaneurol.2021.3188","article-title":"Use and safety of immunotherapeutic management of N-methyl-d-aspartate receptor antibody encephalitis: a meta-analysis.","volume":"78","author":"Nosadini","year":"2021","journal-title":"JAMA Neurol"},{"issue":"5","key":"zoi251061r23","doi-asserted-by":"publisher","first-page":"780","DOI":"10.1212\/WNL.57.5.780","article-title":"Stiff person syndrome: quantification, specificity, and intrathecal synthesis of GAD65 antibodies.","volume":"57","author":"Dalakas","year":"2001","journal-title":"Neurology"},{"issue":"5","key":"zoi251061r24","doi-asserted-by":"publisher","DOI":"10.1212\/NXI.0000000000200011","article-title":"Long-term effectiveness of IVIg maintenance therapy in 36 patients with GAD antibody-positive stiff-person syndrome.","volume":"9","author":"Yi","year":"2022","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"zoi251061r25","doi-asserted-by":"publisher","DOI":"10.1016\/j.jneuroim.2025.578651","article-title":"An updated, comprehensive meta-analysis of the treatment of anti-NMDAR encephalitis: analysis, equipoise, and the urgent need for evidence over anecdote.","volume":"405","author":"Hoshina","year":"2025","journal-title":"J Neuroimmunol"},{"issue":"1","key":"zoi251061r26","doi-asserted-by":"publisher","first-page":"22","DOI":"10.4161\/mabs.22771","article-title":"Epitope interactions of monoclonal antibodies targeting CD20 and their relationship to functional properties.","volume":"5","author":"Klein","year":"2013","journal-title":"MAbs"},{"issue":"6","key":"zoi251061r27","doi-asserted-by":"publisher","first-page":"546","DOI":"10.1056\/NEJMoa1917246","article-title":"Ofatumumab versus teriflunomide in multiple sclerosis.","volume":"383","author":"Hauser","year":"2020","journal-title":"N Engl J Med"},{"issue":"3","key":"zoi251061r28","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1056\/NEJMoa1601277","article-title":"Ocrelizumab versus interferon beta-1a in relapsing multiple sclerosis.","volume":"376","author":"Hauser","year":"2017","journal-title":"N Engl J Med"},{"issue":"4","key":"zoi251061r29","doi-asserted-by":"publisher","first-page":"460","DOI":"10.1002\/ana.21867","article-title":"Rituximab in patients with primary progressive multiple sclerosis: results of a randomized double-blind placebo-controlled multicenter trial.","volume":"66","author":"Hawker","year":"2009","journal-title":"Ann Neurol"},{"issue":"8","key":"zoi251061r30","doi-asserted-by":"publisher","first-page":"704","DOI":"10.1056\/NEJMoa2201904","article-title":"Ublituximab versus teriflunomide in relapsing multiple sclerosis.","volume":"387","author":"Steinman","year":"2022","journal-title":"N Engl J Med"},{"issue":"8","key":"zoi251061r31","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1016\/S1474-4422(22)00209-5","article-title":"Safety and efficacy of rituximab versus dimethyl fumarate in patients with relapsing-remitting multiple sclerosis or clinically isolated syndrome in Sweden: a rater-blinded, phase 3, randomised controlled trial.","volume":"21","author":"Svenningsson","year":"2022","journal-title":"Lancet Neurol"},{"issue":"6","key":"zoi251061r42","doi-asserted-by":"publisher","DOI":"10.1001\/jamahealthforum.2021.0626","article-title":"Estimating rebates and other discounts received by Medicare Part D.","volume":"2","author":"Feldman","year":"2021","journal-title":"JAMA Health Forum"},{"issue":"3","key":"zoi251061r43","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1001\/jamaneurol.2013.5857","article-title":"Neuromyelitis optica spectrum disorders with aquaporin-4 and myelin-oligodendrocyte glycoprotein antibodies: a comparative study.","volume":"71","author":"Kitley","year":"2014","journal-title":"JAMA Neurol"},{"issue":"6","key":"zoi251061r44","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1212\/WNL.0000000000000101","article-title":"Distinction between MOG antibody-positive and AQP4 antibody-positive NMO spectrum disorders.","volume":"82","author":"Sato","year":"2014","journal-title":"Neurology"},{"key":"zoi251061r10","unstructured":"Appendix 1: cost comparison table. In: Pharmacoeconomic Report: Satralizumab (Enspryng). Canadian Agency for Drugs and Technologies in Health; 2021. Accessed October 22, 2024. https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK583282\/"},{"key":"zoi251061r11","unstructured":"Table 4, summary of economic evaluation. In: Inebilizumab (Uplizna). Canadian Agency for Drugs and Technologies in Health; 2024. Accessed October 22, 2024. https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK604416\/table\/t04\/"},{"key":"zoi251061r16","unstructured":"Medicare Part D prescribers - by provider. Centers for Medicare & Medicaid Services. Accessed October 24, 2024. https:\/\/data.cms.gov\/provider-summary-by-type-of-service\/medicare-part-d-prescribers\/medicare-part-d-prescribers-by-provider"},{"key":"zoi251061r18","unstructured":"Consumer Price Index (CPI) databases. US Bureau of Labor Statistics. Accessed October 24, 2024. https:\/\/www.bls.gov\/cpi\/data.htm"},{"key":"zoi251061r19","unstructured":"Measuring price change in the CPI: medical care. US Bureau of Labor Statistics. Accessed October 24, 2024. https:\/\/www.bls.gov\/cpi\/factsheets\/medical-care.htm"},{"key":"zoi251061r32","unstructured":"Federal report finds most prescription drug prices up: Boston25: January 22, 2024. Health Care For All. Accessed November 8, 2024. https:\/\/hcfama.org\/federal-report-finds-most-prescription-drug-prices-up-boston25-january-22-2024\/"},{"key":"zoi251061r33","unstructured":"Mylan brings critical access to the multiple sclerosis community by launching a more affordable treatment option through a first generic to Tecfidera. Mylan. August 19, 2020. Accessed November 8, 2024. https:\/\/investor.mylan.com\/news-releases\/news-release-details\/mylan-brings-critical-access-multiple-sclerosis-community"},{"key":"zoi251061r34","unstructured":"FDA approves Mavenclad (cladribine) tables as first and only short-course oral treatment for relapsing-remitting and active secondary progressive multiple sclerosis. EMD Serono. Accessed November 8, 2024. https:\/\/www.multivu.com\/players\/English\/8485951-emd-serono-mavenclad-fda-approval"},{"key":"zoi251061r35","unstructured":"Drug approval package: Aubagio (teriflunomide) tablets. US Food and Drug Administration. Accessed November 8, 2024. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2012\/202992Orig1s000TOC.cfm"},{"key":"zoi251061r36","unstructured":"Drug approval package: Tysabri (natalizumab). US Food and Drug Administration. Accessed November 8, 2024. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2004\/125104s000_natalizumab.cfm"},{"key":"zoi251061r37","unstructured":"Prescribing information for Lemtrada (alemtuzumab) injection. US Food and Drug Administration. Accessed November 8, 2024. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2014\/103948s5139lbl.pdf"},{"key":"zoi251061r38","unstructured":"NHE Fact Sheet. Centers for Medicare & Medicaid Services. Accessed November 8, 2024. https:\/\/www.cms.gov\/data-research\/statistics-trends-and-reports\/national-health-expenditure-data\/nhe-fact-sheet"},{"key":"zoi251061r39","unstructured":"Medicare Drug Price Negotiation Program. Centers for Medicare & Medicaid Services. Accessed November 8, 2024. https:\/\/www.cms.gov\/inflation-reduction-act-and-medicare\/medicare-drug-price-negotiation"},{"key":"zoi251061r40","unstructured":"Fein? AJ. Warped incentives update: the gross-to-net bubble exceeded $200 billion in 2021 (rerun). Drug Channels. July 26, 2022. Accessed April 11, 2025. https:\/\/www.drugchannels.net\/2022\/07\/warped-incentives-update-gross-to-net.html"},{"key":"zoi251061r41","unstructured":"Pharmacy benefit managers: the powerful middlemen inflating drug costs and squeezing main street pharmacies. Federal Trade Commission. July 2024. Accessed November 9, 2024. https:\/\/www.ftc.gov\/reports\/pharmacy-benefit-managers-report"}],"container-title":["JAMA Network Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/articlepdf\/2840356\/wong_2025_oi_251061_1760388419.53255.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,20]],"date-time":"2025-10-20T15:31:04Z","timestamp":1760974264000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/fullarticle\/2840356"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,20]]},"references-count":44,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2025,10,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamanetworkopen.2025.38277","relation":{},"ISSN":["2574-3805"],"issn-type":[{"value":"2574-3805","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,20]]}}}